Definitive Radiotherapy or Chemoradiotherapy in the Treatment of Merkel Cell Carcinoma

Puma Sundaresan, George Hruby, Anne Hamilton, Angela Hong, Michael Boyer, Mark Chatfield, John Thompson

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Aims: Merkel cell carcinoma (MCC) is a radiosensitive tumour. Radiotherapy has an important role in its treatment, including definitive management. This study aimed to determine the in-field control achieved with definitive radiotherapy or chemoradiotherapy (CRT) and to examine patterns of relapse.

Materials and methods:
Patients treated with definitive radiotherapy or CRT for biopsy-confirmed MCC were identified from records of the Royal Prince Alfred Hospital and Melanoma Institute Australia. Definitive treatment was defined as treatment delivered to macroscopic or residual microscopic disease at the primary site or in regional nodes. Patients with distant metastatic disease at presentation and those treated electively or adjuvantly (i.e. after microscopically clear excision) were excluded.

Results: Of 26 patients treated with definitive radiotherapy (n = 18) or CRT (n = 8), 20 were disease free at last follow-up (median follow-up 23.5 months). Five of the six patients who recurred did so at distant sites, with two experiencing simultaneous in-field failure at treated nodal sites where there had been macroscopic disease at presentation. Eighty-nine per cent of all patients and 85% of those with macroscopic disease were free of in-field recurrence at 2 years.

Conclusion: Definitive radiotherapy or CRT produces excellent in-field disease control in the treatment of primary and regionally metastatic MCC.
Original languageEnglish
Pages (from-to)e131-e136
Number of pages6
JournalClinical Oncology
Volume24
Issue number9
DOIs
Publication statusPublished - 2012

Fingerprint

Merkel Cell Carcinoma
Chemoradiotherapy
Radiotherapy
Therapeutics
Recurrence
Melanoma
Biopsy
Neoplasms

Cite this

Sundaresan, P., Hruby, G., Hamilton, A., Hong, A., Boyer, M., Chatfield, M., & Thompson, J. (2012). Definitive Radiotherapy or Chemoradiotherapy in the Treatment of Merkel Cell Carcinoma. Clinical Oncology, 24(9), e131-e136. https://doi.org/10.1016/j.clon.2012.04.007
Sundaresan, Puma ; Hruby, George ; Hamilton, Anne ; Hong, Angela ; Boyer, Michael ; Chatfield, Mark ; Thompson, John. / Definitive Radiotherapy or Chemoradiotherapy in the Treatment of Merkel Cell Carcinoma. In: Clinical Oncology. 2012 ; Vol. 24, No. 9. pp. e131-e136.
@article{4accc84195f84e4484fefaaef75d7160,
title = "Definitive Radiotherapy or Chemoradiotherapy in the Treatment of Merkel Cell Carcinoma",
abstract = "Aims: Merkel cell carcinoma (MCC) is a radiosensitive tumour. Radiotherapy has an important role in its treatment, including definitive management. This study aimed to determine the in-field control achieved with definitive radiotherapy or chemoradiotherapy (CRT) and to examine patterns of relapse.Materials and methods: Patients treated with definitive radiotherapy or CRT for biopsy-confirmed MCC were identified from records of the Royal Prince Alfred Hospital and Melanoma Institute Australia. Definitive treatment was defined as treatment delivered to macroscopic or residual microscopic disease at the primary site or in regional nodes. Patients with distant metastatic disease at presentation and those treated electively or adjuvantly (i.e. after microscopically clear excision) were excluded.Results: Of 26 patients treated with definitive radiotherapy (n = 18) or CRT (n = 8), 20 were disease free at last follow-up (median follow-up 23.5 months). Five of the six patients who recurred did so at distant sites, with two experiencing simultaneous in-field failure at treated nodal sites where there had been macroscopic disease at presentation. Eighty-nine per cent of all patients and 85{\%} of those with macroscopic disease were free of in-field recurrence at 2 years.Conclusion: Definitive radiotherapy or CRT produces excellent in-field disease control in the treatment of primary and regionally metastatic MCC.",
author = "Puma Sundaresan and George Hruby and Anne Hamilton and Angela Hong and Michael Boyer and Mark Chatfield and John Thompson",
year = "2012",
doi = "10.1016/j.clon.2012.04.007",
language = "English",
volume = "24",
pages = "e131--e136",
journal = "Clinical Oncology",
issn = "0936-6555",
publisher = "W.B. Saunders",
number = "9",

}

Sundaresan, P, Hruby, G, Hamilton, A, Hong, A, Boyer, M, Chatfield, M & Thompson, J 2012, 'Definitive Radiotherapy or Chemoradiotherapy in the Treatment of Merkel Cell Carcinoma', Clinical Oncology, vol. 24, no. 9, pp. e131-e136. https://doi.org/10.1016/j.clon.2012.04.007

Definitive Radiotherapy or Chemoradiotherapy in the Treatment of Merkel Cell Carcinoma. / Sundaresan, Puma; Hruby, George; Hamilton, Anne; Hong, Angela; Boyer, Michael; Chatfield, Mark; Thompson, John.

In: Clinical Oncology, Vol. 24, No. 9, 2012, p. e131-e136.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Definitive Radiotherapy or Chemoradiotherapy in the Treatment of Merkel Cell Carcinoma

AU - Sundaresan, Puma

AU - Hruby, George

AU - Hamilton, Anne

AU - Hong, Angela

AU - Boyer, Michael

AU - Chatfield, Mark

AU - Thompson, John

PY - 2012

Y1 - 2012

N2 - Aims: Merkel cell carcinoma (MCC) is a radiosensitive tumour. Radiotherapy has an important role in its treatment, including definitive management. This study aimed to determine the in-field control achieved with definitive radiotherapy or chemoradiotherapy (CRT) and to examine patterns of relapse.Materials and methods: Patients treated with definitive radiotherapy or CRT for biopsy-confirmed MCC were identified from records of the Royal Prince Alfred Hospital and Melanoma Institute Australia. Definitive treatment was defined as treatment delivered to macroscopic or residual microscopic disease at the primary site or in regional nodes. Patients with distant metastatic disease at presentation and those treated electively or adjuvantly (i.e. after microscopically clear excision) were excluded.Results: Of 26 patients treated with definitive radiotherapy (n = 18) or CRT (n = 8), 20 were disease free at last follow-up (median follow-up 23.5 months). Five of the six patients who recurred did so at distant sites, with two experiencing simultaneous in-field failure at treated nodal sites where there had been macroscopic disease at presentation. Eighty-nine per cent of all patients and 85% of those with macroscopic disease were free of in-field recurrence at 2 years.Conclusion: Definitive radiotherapy or CRT produces excellent in-field disease control in the treatment of primary and regionally metastatic MCC.

AB - Aims: Merkel cell carcinoma (MCC) is a radiosensitive tumour. Radiotherapy has an important role in its treatment, including definitive management. This study aimed to determine the in-field control achieved with definitive radiotherapy or chemoradiotherapy (CRT) and to examine patterns of relapse.Materials and methods: Patients treated with definitive radiotherapy or CRT for biopsy-confirmed MCC were identified from records of the Royal Prince Alfred Hospital and Melanoma Institute Australia. Definitive treatment was defined as treatment delivered to macroscopic or residual microscopic disease at the primary site or in regional nodes. Patients with distant metastatic disease at presentation and those treated electively or adjuvantly (i.e. after microscopically clear excision) were excluded.Results: Of 26 patients treated with definitive radiotherapy (n = 18) or CRT (n = 8), 20 were disease free at last follow-up (median follow-up 23.5 months). Five of the six patients who recurred did so at distant sites, with two experiencing simultaneous in-field failure at treated nodal sites where there had been macroscopic disease at presentation. Eighty-nine per cent of all patients and 85% of those with macroscopic disease were free of in-field recurrence at 2 years.Conclusion: Definitive radiotherapy or CRT produces excellent in-field disease control in the treatment of primary and regionally metastatic MCC.

U2 - 10.1016/j.clon.2012.04.007

DO - 10.1016/j.clon.2012.04.007

M3 - Article

VL - 24

SP - e131-e136

JO - Clinical Oncology

JF - Clinical Oncology

SN - 0936-6555

IS - 9

ER -

Sundaresan P, Hruby G, Hamilton A, Hong A, Boyer M, Chatfield M et al. Definitive Radiotherapy or Chemoradiotherapy in the Treatment of Merkel Cell Carcinoma. Clinical Oncology. 2012;24(9):e131-e136. https://doi.org/10.1016/j.clon.2012.04.007